SRNE Sorrento Therapeutics, Inc. Stock Quote

SRNE [NASD]

Index	-	P/E	-	EPS (ttm)	-1.46	Insider Own	15.71%	Shs Outstand	251.21M	Perf Week	51.84%
Market Cap	4.15B	Forward P/E	4.81	EPS next Y	3.17	Insider Trans	0.00%	Shs Float	221.63M	Perf Month	93.03%
Income	-289.80M	PEG	-	EPS next Q	3.74	Inst Own	28.00%	Short Float	33.20%	Perf Quarter	92.30%
Sales	41.50M	P/S	99.90	EPS this Y	-14.80%	Inst Trans	0.91%	Short Ratio	4.72	Perf Half Y	102.80%
Book/sh	0.82	P/B	18.57	EPS next Y	15.93%	ROA	-52.00%	Target Price	-	Perf Year	276.05%
Cash/sh	-	P/C	-	EPS next 5Y	37.00%	ROE	-221.90%	52W Range	1.55 - 19.39	Perf YTD	123.15%
Dividend	-	P/FCF	-	EPS past 5Y	-11.10%	ROI	-91.30%	52W High	-21.45%	Beta	2.58
Dividend %	-	Quick Ratio	1.10	Sales past 5Y	52.40%	Gross Margin	78.80%	52W Low	882.58%	ATR	1.21
Employees	310	Current Ratio	1.20	Sales Q/Q	103.40%	Oper. Margin	-	RSI (14)	82.97	Volatility	20.18% 11.39%
Optionable	Yes	Debt/Eq	0.82	EPS Q/Q	32.10%	Profit Margin	-	Rel Volume	7.00	Prev Close	10.42
Shortable	Yes	LT Debt/Eq	0.73	Earnings	-	Payout	-	Avg Volume	15.60M	Price	15.23
Recom	2.00	SMA20	87.39%	SMA50	97.09%	SMA200	108.81%	Volume	109,272,760	Change	46.16%

Jan-21-21

Initiated

Alliance Global Partners

Buy

$35

Jul-31-20

Reiterated

H.C. Wainwright

Buy

$24 → $30

May-26-20

Initiated

Dawson James

Buy

$24

Oct-07-19

Initiated

JMP Securities

Mkt Outperform

$21

Jun-28-18

Initiated

B. Riley FBR, Inc.

Buy

$14.25

Jan-16-18

Reiterated

H.C. Wainwright

Buy

$20 → $30

May-22-17

Reiterated

Rodman & Renshaw

Buy

$30 → $20

May-22-17

Reiterated

FBR & Co.

Outperform

$13 → $9

Oct-03-16

Initiated

ROTH Capital

Buy

Apr-06-16

Reiterated

FBR Capital

Outperform

$21 → $16

Mar-16-16

Reiterated

FBR Capital

Outperform

$22 → $21

Dec-22-15

Initiated

FBR Capital

Outperform

$22

Dec-07-15

Resumed

Rodman & Renshaw

Buy

$45

Aug-03-15

Resumed

MLV & Co

Buy

$34

Jul-29-15

Reiterated

Brean Capital

Buy

$17 → $26

May-28-15

Initiated

Brean Capital

Buy

$17

Mar-17-15

Reiterated

H.C. Wainwright

Buy

$13 → $20

Oct-02-14

Initiated

H.C. Wainwright

Buy

$11

Jun-19-14

Initiated

MLV & Co

Buy

Dec-03-13

Initiated

Aegis Capital

Buy

$40

Jan-27-21 01:06PM	Stocks Showing Market Leadership: Sorrento Therapeutics Earns 93 RS Rating Investor's Business Daily +46.16%
12:42PM	Why Sorrento Therapeutics Stock Is Skyrocketing Today Motley Fool
07:35AM	The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga
Jan-26-21 07:09PM	Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC for Treatment of ICU COVID-19 Patients GlobeNewswire +12.28%
Jan-25-21 04:22PM	Sorrento Stock Has Multiple Catalysts in Play; Analyst Says Buy TipRanks
Jan-22-21 06:48AM	Where Will Sorrento Therapeutics Be in 1 Year? Motley Fool
Jan-19-21 05:06PM	Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein GlobeNewswire
08:54AM	Do Options Traders Know Something About Sorrento (SRNE) Stock We Don't? Zacks
02:06AM	Dr. Henry Ji to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 20, 2021 GlobeNewswire
Jan-14-21 08:31PM	Sorrento Stock Could Hit $30, Says Analyst TipRanks +9.90%
Jan-10-21 05:58PM	Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference GlobeNewswire
Jan-06-21 05:45PM	Sorrento Therapeutics (SRNE) Stock Sinks As Market Gains: What You Should Know Zacks
Dec-30-20 12:48PM	Sorrento Announces the Submission of a Marketing Authorization Application to COFEPRIS (Mexico) for COVI-STIX Rapid Detection Test of SARS-CoV-2 Viral Antigen GlobeNewswire +5.31%
Dec-24-20 10:02AM	Company News for Dec 24, 2020 Zacks -7.83%
Dec-23-20 02:55PM	Sorrento Up on Request for Emergency Authorization for Covid Test TheStreet.com +18.56%
01:53PM	COVID News Flow: Pfizer-BioNTech's US Vaccine Supply Deal, Merck Strikes $356M Contract, Sorrento Files For EUA Of Rapid Test Benzinga
Dec-22-20 06:59PM	Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX Rapid Test for the Detection of SARS-CoV-2 Viral Antigen GlobeNewswire -5.12%
Dec-14-20 12:06AM	Is SRNE A Good Stock To Buy Now? Insider Monkey
Dec-10-20 09:56AM	Unusual Options Activity Insight: Sorrento Therapeutics Benzinga
Dec-09-20 01:27PM	Sorrento Therapeutics Cleared to Start Trial for Its Next-Generation Coronavirus Antibody Treatment Motley Fool
12:25PM	Why Sorrento And Infinity Are Moving Today Benzinga
11:33AM	Biotech CEOs Talk Vision, Cash Burn, Catalysts At Benzinga Global Small Cap Conference Benzinga
09:00AM	Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed COVID-19 Patients GlobeNewswire
07:23AM	The Daily Biotech Pulse: Roche & Moderna Strike COVID Testing Partnership, Rocket Pharma's Gene Therapy Readout, Breast Cancer Presentations Benzinga
Dec-08-20 08:06PM	Sorrento Receives Licensure From the State of California for Clinical Testing Laboratory (CLIA) Allowing for Clinical Sample Testing GlobeNewswire
Dec-04-20 04:21PM	Dont Chase the Rebound in Sorrento Its Not Worth the Risk InvestorPlace
01:48PM	The Shock and Awe of Sorrento Therapeutics Is Long Gone InvestorPlace
Dec-02-20 07:04AM	Should You Follow Robinhood Investors Into These 2 Risky Coronavirus Stocks? Motley Fool
Nov-29-20 08:19PM	Sorrento to Participate in the 32nd Piper Sandler Healthcare Investor Conference GlobeNewswire
Nov-27-20 11:41AM	These 3 Coronavirus Vaccine Stocks Are Lifting the Nasdaq to New Records Motley Fool +18.12%
10:37AM	Sorrento Receives $34M Federal Contract for Covid Treatment TheStreet.com
10:10AM	Sorrento Gets DARPA Contract For Up To $34M To Develop Neutralizing Antibodies For COVID-19 Benzinga
09:58AM	Why Sorrento Therapeutics Stock Is Ripping Higher Today Motley Fool
08:00AM	DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies GlobeNewswire
Nov-23-20 04:11PM	What Should Sorrento Therapeutics' Investors Look for in the Months Ahead? Motley Fool
10:09AM	Sorrento Therapeutics' Multifaceted Plan to Attack COVID-19 Motley Fool
Nov-22-20 02:27PM	Sorrento Therapeutics' Slow-But-Steady Approach to COVID-19 Motley Fool
11:28AM	Sorrento Therapeutics Plans to Cut Development of Its Coronavirus Vaccine if the Leaders' Vaccines Work Motley Fool
07:31AM	Could Sorrento Therapeutics Be a Millionaire-Maker Stock? Motley Fool
Nov-21-20 01:16PM	Sorrento Therapeutics' Next-Generation COVID-19 Therapeutic Antibody Motley Fool
07:28AM	Is There Room for Latecomers to the COVID-19 Party? Motley Fool
Nov-20-20 04:08PM	Sorrento Therapeutics on COVID-19 Therapy Competition: "Our Antibody Is Better Than Theirs" Motley Fool
10:40AM	Sorrento Therapeutics' CEO Henry Ji on the Status of the Company's 3 COVID-19 Tests Motley Fool
07:02AM	Is Sorrento Therapeutics Stock a Buy? Motley Fool
Nov-19-20 04:24PM	How Will Sorrento Therapeutics Deal With the Added COVID-19 Competition? Motley Fool +11.68%
10:07AM	Sorrento CEO Henry Ji on How the Company Got Its Start Motley Fool
Nov-16-20 10:00AM	Novavax and Sorrento Therapeutics: Are These Beaten-Down Coronavirus Stocks a Bargain? Motley Fool
Nov-15-20 06:14AM	3 Ultra-Risky Robinhood Stocks That Just Might Make You a Fortune Motley Fool
Nov-12-20 08:31AM	Is the Options Market Predicting a Spike in Sorrento Therapeutics (SRNE) Stock? Zacks -6.73%
Nov-11-20 12:18PM	Why Sorrento Therapeutics Stock Is Jumping Today Motley Fool +11.04%
09:00AM	Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2 GlobeNewswire
Nov-09-20 06:39PM	Sorrento Therapeutics Files IND for Coronavirus Treatment Motley Fool -17.48%
06:16PM	Here's Why Sorrento Therapeutics Plummeted 37.8% in October Motley Fool
09:00AM	Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2 GlobeNewswire
Nov-06-20 12:30PM	Will Sorrento Therapeutics (SRNE) Report Negative Q3 Earnings? What You Should Know Zacks
Nov-04-20 10:12AM	Sorrento (SRNE) to Report Q3 Earnings: What's in the Cards? Zacks
Nov-03-20 05:45PM	Sorrento Therapeutics (SRNE) Gains But Lags Market: What You Should Know Zacks
Oct-31-20 06:25AM	These 2 Robinhood Favorites Could Double by 2022 Motley Fool
Oct-29-20 09:00AM	Sorrento Announces That Intranasal Administration of COVI-AMG Neutralizing Antibody Prevented COVID-19 Disease Progression in Infected Hamsters Following SARS-CoV-2 Infection GlobeNewswire
Oct-28-20 11:28AM	2 Coronavirus Stocks That Will Falter in a Market Crash Motley Fool -8.04%
Oct-26-20 05:45PM	Sorrento Therapeutics (SRNE) Dips More Than Broader Markets: What You Should Know Zacks
Oct-25-20 07:00AM	Is Sorrento Therapeutics Stock a Buy? Motley Fool
Oct-22-20 04:08PM	3 Reasons to Take a Chance on Sorrento Stock InvestorPlace +5.48%
07:15AM	Is Sorrento Therapeutics a Ticking Time Bomb for Investors? Motley Fool
Oct-21-20 03:50PM	Sorrento Therapeutics Is a Vaccine Movie That Investors Have Already Seen InvestorPlace
Oct-20-20 10:05AM	Beware of Investing in These 3 Small-Cap Coronavirus Stocks Motley Fool -7.54%
Oct-19-20 01:44PM	Tests, Treatments, Vaccines: Sorrento Therapeutics Is All In on COVID-19 Motley Fool
Oct-18-20 06:25AM	2 Top Robinhood Stocks to Sell Before the Next Market Crash Motley Fool
Oct-17-20 06:11AM	Better Coronavirus Stock: Moderna vs. Sorrento Therapeutics Motley Fool
Oct-16-20 06:43PM	Why Sorrento Therapeutics Stock Cratered on Friday Motley Fool -10.49%
09:01AM	Sorrento Therapeutics Stock Is Not That Attractive Now TheStreet.com
Oct-15-20 09:20AM	Brazil Healthcare Regulator Authorizes Sorrento Therapeutics' Phase 2 Trial for Coronavirus Drug Candidate Motley Fool
Oct-14-20 12:00PM	Why Sorrento Therapeutics Is Tanking Today Motley Fool -15.48%
11:57AM	Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients GlobeNewswire
Oct-13-20 08:20AM	The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data Benzinga
02:51AM	Sorrento Adds Stem Cell Treatment To Covid-19 Pipeline; Shares Rise SmarterAnalyst
Oct-12-20 08:01PM	Sorrento Therapeutics Adds Another COVID-19 Treatment to Its Pipeline Motley Fool
05:21PM	Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies GlobeNewswire
Oct-09-20 07:46PM	Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released GlobeNewswire
05:45PM	Sorrento Therapeutics (SRNE) Outpaces Stock Market Gains: What You Should Know Zacks
02:09PM	Sorrento Stock Investors Should Play Powerball Instead InvestorPlace
Oct-07-20 04:44PM	Why Sorrento Therapeutics Stock Jumped Today Motley Fool +9.14%
03:10PM	Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies and Highlights its Place in a Potential Multi-Modal Therapy Strategy in Combination With Neutralizing Antibodies Against COVID-19 GlobeNewswire
09:00AM	Why Sorrento Therapeutics Stock Bolted Higher in September Motley Fool
06:00AM	Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA) Phase 3 Pivotal Trial Program in 2020 GlobeNewswire
Oct-06-20 12:04PM	If COVID-19 Antibody Cocktails Become Popular, Sorrento Stock Could Double, Says Analyst TipRanks
11:13AM	Chart Patterns Point to Higher Prices for Micro Caps Investopedia
Oct-04-20 06:39PM	Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline GlobeNewswire
Oct-02-20 09:57AM	Sorrento Therapeutics Is Simply Running Out of Time InvestorPlace
09:57AM	Sorrento Therapeutics Is Simply Running Out of Time CoinDesk
09:30AM	Sorrento & ViralClear Explore Combination Coronavirus Treatments Zacks
Sep-30-20 03:04PM	17 Reasons to Be Excited About Sorrento Therapeutics and 1 Big Reason to Be Very Worried Motley Fool
09:50AM	Company News for Sep 30, 2020 Zacks
09:27AM	SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19 GlobeNewswire
09:00AM	Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19 GlobeNewswire
Sep-29-20 11:53AM	Why Sorrento Therapeutics Stock Is Surging Today Motley Fool +14.29%
09:05AM	Sorrento Identifies Second 'More Potent' Anti-COVID-19 Antibody For Clinical Testing Benzinga
07:47AM	The Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut Benzinga
Sep-28-20 11:59PM	Sorrento Releases Preclinical Data for STI-1499 (COVI-Guard) and STI-2020 (COVI-AMG), Potent Neutralizing Antibodies Against SARS-CoV-2 GlobeNewswire +5.35%
10:32AM	Is Sorrento Stock a Buy Right Now? This Is What You Need to Know TipRanks

Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Followwill Dorman	Director	Dec 16	Sale	7.14	1,000	7,135	2,130	Jan 26 05:24 PM
Smith Robin L	Director	Mar 05	Buy	2.27	40,000	90,896	60,000	Mar 05 01:58 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience